NCT06629272 Optimizing Care for Older Adults Through Thyroid Hormone Deprescribing
| NCT ID | NCT06629272 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan |
| Condition | Hypothyroidism |
| Study Type | INTERVENTIONAL |
| Enrollment | 900 participants |
| Start Date | 2024-12-02 |
| Primary Completion | 2029-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 900 participants in total. It began in 2024-12-02 with a primary completion date of 2029-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The proposed study focuses on testing a novel adapted evidence-based multilevel intervention, Deprescribing Thyroid Hormone In Older Adults (D-THIO), to support thyroid hormone deprescribing (dose de-escalation and/or discontinuation) in older adults with thyroid hormone overtreatment and/or misuse and reduce patient harm. Findings from this study will lay the groundwork for broad implementation of D-THIO and serve as a model for deprescribing inappropriate medications for other endocrine conditions and conditions with biochemical monitoring.
Eligibility Criteria
Patient Eligibility: Inclusion Criteria: 1. age 65 years and older 2. on thyroid hormone therapy and have a serum Thyroid-stimulating hormone (TSH) \<0.5 mIU/L or are on thyroid hormone therapy for an inappropriate indication 3. English speaking 4. without cognitive impairment Exclusion Criteria: 1\) Patients with a diagnosis of thyroid cancer, secondary hypothyroidism, history of total thyroidectomy or hospitalization in the past 3 months will be excluded. Provider eligibility: Inclusion: Primary care physicians, endocrinologists, geriatricians, and Advanced Practice Providers (APPs) who practice at University of Michigan, Henry Ford Health System or University of California San Fransico (UCSF) and who prescribe thyroid hormone for eligible patients identified above will be eligible for study participation. Exclusion: Providers who don't prescribe thyroid hormone.
Contact & Investigator
Maria Papaleontiou
PRINCIPAL INVESTIGATOR
University of Michigan
Frequently Asked Questions
Who can join the NCT06629272 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Hypothyroidism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06629272 currently recruiting?
Yes, NCT06629272 is actively recruiting participants. Contact the research team at bbartol@umich.edu for enrollment information.
Where is the NCT06629272 trial being conducted?
This trial is being conducted at San Francisco, United States, Ann Arbor, United States, Detroit, United States.
Who is sponsoring the NCT06629272 clinical trial?
NCT06629272 is sponsored by University of Michigan. The principal investigator is Maria Papaleontiou at University of Michigan. The trial plans to enroll 900 participants.